Literature DB >> 6086214

The in vitro antimicrobial activity of desacetylcefotaxime compared to other related beta-lactams.

E Schrinner, M Limbert, K Seeger, G Seibert, W J Novick.   

Abstract

Like all other cephalosporins that contain an acetyl side chain in the 3' position, cefotaxime (CTX) is partially desacetylated in vivo. Desacetylcefotaxime (des-CTX) possesses a broad antimicrobial spectrum and high beta-lactamase stability. With the exception of Pseudomonas aeruginosa, Morganella morganii, Bacteroides fragilis, and Staphylococcus aureus, most strains of other species tested usually had mean MICs of des-CTX lower than 1 microgram/ml. Its activity is generally lower than that of the parent compound. It was only against some strains of P. cepacia that des-CTX surpassed the activity of CTX. The activity of des-CTX markedly exceeds the activity of many therapeutically used cephalosporins. This is especially true for Haemophilus influenzae, Neisseria meningitidis, most species of Enterobacteriaceae, and streptococci other than Streptococcus faecalis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086214

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  4 in total

1.  Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

Review 2.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 3.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

4.  Clinical experience with cefotaxime for the therapy of bacteremias due to gram-positive organisms.

Authors:  C J Schleupner
Journal:  Infection       Date:  1985       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.